Diligence memo · auto-generated · as of July 3, 2026

Pneuma Respiratory, Inc.

Pneuma Respiratory, Inc. looks fair against its niche peers and is quiet on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Pneuma Respiratory, Inc. operates in Pharmaceuticals, based in BOONE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pneuma Respiratory, Inc. has raised $35M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.1M on 2018-03-13.

Most recent recorded round closed around 2025-02-10.

Valuation (modeled)modeled

Provath models Pneuma Respiratory, Inc. at approximately $13M (range $3.8M–$24M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.80× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 4 months.

Last raise 17 mo ago; this sector typically re-raises about every 13 months.

Slightly overdue versus sector cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 76% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 21% of those peers.

Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.